The Agenda - coming up this week at HealthXL

Every week, HealthXL communities connect to break down some of the major challenges and opportunities in digital health. 

If you are interested in joining any of these meetings, just click through the link to request access. However, even if you can't make a meeting, keep an eye out for the key takeaways, which will be published later this month. 

DTx-drug combinations are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?  

This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. 

Are you a DTx or Pharma company seeking coverage of your DTx in the US market? How should we be thinking about value-based agreements (VBA) in the context of DTx reimbursement in the US? 

Establishing reimbursement and achieving payment not less than real value by payers is key to achieving higher revenues for DTx products. In this masterclass led by biopharma and PDT outcomes-based contracting pioneer, Mike Pace, we will focus on value-based contracts and their application in US DTx market access and payer engagement strategy

Are you a digital health start-up seeking capital to grow your business? A few years ago, getting investors to fund digital health companies was much easier. The market was small and it was not as competitive as it is now, especially in certain therapeutic areas, such as mental health. 

Investors now understand better what the important metrics are and they are more demanding. How has the digital health market evolved? Join this Fireside Chat with Robert Garber, partner at 7wireVentures, focused on both the United States and European markets.